Inovio vaccine trial on partial hold as FDA questions device used
The Cellectra 2000 device is under the spotlight, not the actual vaccine or its positive results, yet Inovio shares dropped 35% in early trade
28 September 2020 - 15:12
London — Inovio Pharmaceuticals has put a partial hold on a phase 2-3 study of its Covid-19 vaccine after US regulators raised questions about a delivery device used in the inoculation.
The US vaccine maker is working to answer questions from the US Food and Drug Administration (FDA) about the Cellectra 2000 device used in the trial, Plymouth Meeting, Pennsylvania-based Inovio said in a statement on Monday. The hold is not due to any adverse events from the vaccine, Inovio said...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.